semustine has been researched along with Rectal Neoplasms in 99 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 9.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "Twenty patients with advanced colorectal carcinoma were treated with combination chemotherapy consisting of actinomycin D, vincristine, methyl-CCNU, and methotrexate." | 7.67 | Treatment of advanced colorectal carcinoma with actinomycin D, vincristine, methyl-CCNU, and methotrexate. ( Cooper, MR; Craig, JB; Jackson, DV; Muss, HB; Richards, FR; Spurr, CL; Stuart, JJ; White, DR, 1987) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 5.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)." | 5.05 | Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "The combination of vincristine, methyl-CCNU, and methotrexate with or without MER-BCG achieved a 2% complete response (CR) and a 11% partial response (PR) with a median duration of 25-29 weeks in 124 evaluable patients with advanced adenocarcinoma of the colon and rectum." | 5.04 | Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum: a prospective randomized study. ( Barnes, P; Cooper, R; Howard, V; Muss, HB; Rhyne, L; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1979) |
| "Twenty patients with advanced colorectal carcinoma were treated with combination chemotherapy consisting of actinomycin D, vincristine, methyl-CCNU, and methotrexate." | 3.67 | Treatment of advanced colorectal carcinoma with actinomycin D, vincristine, methyl-CCNU, and methotrexate. ( Cooper, MR; Craig, JB; Jackson, DV; Muss, HB; Richards, FR; Spurr, CL; Stuart, JJ; White, DR, 1987) |
| "Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients." | 3.66 | Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer. ( Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA, 1981) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "The razoxane-treated patients experienced no significant toxicity apart from a readily reversible mild leukopenia in 52% while gastrointestinal symptoms necessitated stopping the drug in only four patients." | 2.65 | A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer. ( Cassell, PC; Ellis, H; Evans, MG; Gilbert, JM; Hellmann, K; Stoodley, BJ; Wastell, C, 1981) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | 2.64 | Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole. ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| " Preoperative radiotherapy with a dosage of 35-45 Gy can lead to downstaging of rectal cancer." | 2.39 | [Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma]. ( Eble, MJ; Kraus, TW; Raeth, U, 1994) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU." | 1.28 | Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU. ( Block, M; Hirschl, S; Lachowiez, RM; Rios, C, 1990) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | 1.27 | The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| "Cancer is one of the most serious illnesses of the elderly." | 1.27 | Management of cancer in the elderly. Implications of the aging process. ( Neilan, BA, 1985) |
| "Thirty-six patients with advanced colorectal cancer whose disease progressed during treatment with 5-fluorouracil (5-FU) chemotherapy were treated with methyl-CCNU and methotrexate." | 1.27 | Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy. ( Bazos, MJ; Evans, WK; Myers, R; Shepherd, FA; Zorzitto, ML, 1986) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| " Further evaluation of vindesine will require dosage modification." | 1.26 | Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea. ( Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982) |
| "Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months." | 1.26 | Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981) |
| "Fifty-two patients with advanced colorectal cancer were treated with a combination of 5-Fluorouracil (FU) plus methyl-1,3-cis (2-chlorethyl)-1-nitrosourea (MeCCNU)." | 1.26 | Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. ( Frei, E; Lokich, JJ; Mayer, RJ; Skarin, AT, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 79 (79.80) | 18.7374 |
| 1990's | 18 (18.18) | 18.2507 |
| 2000's | 2 (2.02) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higgins, GA | 3 |
| Donaldson, RC | 1 |
| Rogers, LS | 1 |
| Juler, GL | 1 |
| Keehn, RJ | 2 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| Togni, P | 1 |
| Sessa, C | 1 |
| Varini, M | 1 |
| Cavalli, F | 1 |
| Kemeny, N | 4 |
| Yagoda, A | 3 |
| Braun, D | 3 |
| Weltz, MD | 1 |
| Perry, DJ | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Amadeo, JH | 1 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Wilson, RE | 1 |
| Hine, KR | 1 |
| Dykes, PW | 1 |
| Engstrom, PF | 4 |
| MacIntyre, JM | 4 |
| Mittelman, A | 7 |
| Klaassen, DJ | 3 |
| Lagomarsino Caprino, MC | 1 |
| Mazzei, T | 1 |
| De Vecchis, L | 1 |
| Popoli, P | 1 |
| Periti, P | 1 |
| Roth, A | 1 |
| Kolarić, K | 1 |
| Windschitl, H | 1 |
| Scott, M | 3 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 1 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Mechl, Z | 1 |
| Ahmann, FR | 1 |
| Douglass, HO | 7 |
| Muggia, F | 2 |
| Moayeri, H | 2 |
| DiBenedetto, J | 2 |
| Gilbert, JM | 1 |
| Cassell, PC | 1 |
| Ellis, H | 1 |
| Wastell, C | 1 |
| Hellmann, K | 1 |
| Evans, MG | 1 |
| Stoodley, BJ | 1 |
| Stroehlein, JR | 1 |
| Bedikian, AY | 2 |
| Karlin, DA | 1 |
| Valdivieso, M | 2 |
| Bennetts, RW | 1 |
| Bodey, GP | 2 |
| Whitehouse, JM | 1 |
| Duncan, W | 1 |
| Windschitl, HE | 1 |
| Krook, JE | 4 |
| Everson, LK | 2 |
| Cullinan, SA | 2 |
| Aroney, RS | 1 |
| Dalley, DN | 1 |
| Chan, WK | 1 |
| Bell, DR | 1 |
| Levi, JA | 1 |
| Golbey, R | 2 |
| Zimm, S | 1 |
| Wampler, GL | 1 |
| Tarquini, A | 1 |
| Mascia, V | 1 |
| Massidda, B | 1 |
| Chessa, PP | 1 |
| Pellegrini, A | 1 |
| Epenetos, AA | 1 |
| Amos, C | 1 |
| Collis, C | 1 |
| Slevin, M | 1 |
| Rohatiner, A | 1 |
| Baille-Johnson, H | 1 |
| Pitts, J | 1 |
| Wrigley, PF | 1 |
| Martin, WR | 1 |
| Riemann, JF | 1 |
| Kraus, TW | 1 |
| Eble, MJ | 1 |
| Raeth, U | 1 |
| Ilson, DH | 1 |
| Kelsen, DP | 1 |
| Mezger, J | 1 |
| Johnston, PG | 1 |
| Fisher, ER | 3 |
| Rockette, HE | 1 |
| Fisher, B | 3 |
| Wolmark, N | 3 |
| Drake, JC | 1 |
| Chabner, BA | 1 |
| Allegra, CJ | 1 |
| O'Connell, MJ | 3 |
| Martenson, JA | 1 |
| Wieand, HS | 3 |
| Macdonald, JS | 4 |
| Haller, DG | 1 |
| Mayer, RJ | 3 |
| Gunderson, LL | 3 |
| Rich, TA | 1 |
| Kodaira, S | 1 |
| Hyams, DM | 1 |
| Colangelo, L | 1 |
| Dimitrov, NV | 1 |
| Romond, EH | 1 |
| Wexler, M | 1 |
| Prager, D | 1 |
| Cruz, AB | 2 |
| Gordon, PH | 1 |
| Petrelli, NJ | 1 |
| Deutsch, M | 2 |
| Mamounas, E | 1 |
| Wickerham, DL | 2 |
| Rockette, H | 2 |
| Hay, JM | 1 |
| Msika, S | 1 |
| Woolley, PV | 2 |
| Schein, PS | 3 |
| Karrer, K | 1 |
| Denck, H | 1 |
| Pridun, N | 1 |
| Johnson, RJ | 1 |
| Berman, R | 1 |
| Giles, GR | 1 |
| Malhotra, A | 1 |
| Bird, GG | 1 |
| Gajjar, PD | 1 |
| Bunch, GA | 1 |
| Hall, R | 1 |
| Buroker, T | 1 |
| Wojtaszak, B | 1 |
| Dindogru, A | 1 |
| DeMattia, M | 1 |
| Baker, L | 1 |
| Groth, C | 1 |
| Vaitkevicius, VK | 2 |
| Mavligit, GM | 1 |
| Burgess, MA | 1 |
| Rodriguez, V | 1 |
| Lavin, PT | 3 |
| Woll, J | 1 |
| Conroy, JF | 1 |
| Carbone, P | 1 |
| Richards, F | 2 |
| Muss, HB | 3 |
| Cooper, R | 1 |
| White, DR | 3 |
| Stuart, JJ | 3 |
| Howard, V | 1 |
| Barnes, P | 1 |
| Rhyne, L | 1 |
| Spurr, CL | 3 |
| Belt, RJ | 1 |
| Stephens, R | 1 |
| White, LA | 1 |
| Perry, MC | 1 |
| Kardinal, CG | 1 |
| Kennedy, BJ | 1 |
| Weiss, RB | 1 |
| Carey, RW | 2 |
| Brutti, A | 1 |
| Liberati, AM | 1 |
| Biscottini, B | 1 |
| Fatati, G | 1 |
| Sini, S | 1 |
| Barzi, AM | 1 |
| Grignani, F | 1 |
| Evans, JT | 2 |
| Carbone, PP | 1 |
| Joss, RA | 1 |
| Goldberg, RS | 1 |
| Yates, JW | 1 |
| Lokich, JJ | 1 |
| Skarin, AT | 1 |
| Frei, E | 1 |
| Fischetti, MR | 1 |
| Weitzman, SA | 1 |
| Kaufman, S | 1 |
| Kelley, RM | 1 |
| Sohier, WD | 1 |
| Greco, FA | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Oldham, RK | 1 |
| Kane, RC | 1 |
| Cashdollar, MR | 1 |
| Bernath, AM | 1 |
| Kisner, D | 1 |
| Moertel, CG | 7 |
| Carter, SK | 3 |
| Cedermark, BJ | 1 |
| Kaufman, JH | 1 |
| Posey, LE | 1 |
| Morgan, LR | 1 |
| Kisner, DF | 1 |
| Smythe, T | 1 |
| Smith, L | 1 |
| Ravasz, LA | 1 |
| van der Tweel, I | 1 |
| Wils, J | 1 |
| Wagener, DJ | 1 |
| Ducreux, M | 1 |
| Cheson, BD | 1 |
| Collins, RT | 1 |
| Beart, RW | 1 |
| Kubista, TP | 1 |
| Poon, MA | 1 |
| Meyers, WC | 1 |
| Mailliard, JA | 2 |
| Steele, G | 1 |
| Block, M | 1 |
| Lachowiez, RM | 1 |
| Rios, C | 1 |
| Hirschl, S | 1 |
| Willen, M | 1 |
| Schutt, AJ | 3 |
| Buroker, TR | 1 |
| Fleming, TR | 1 |
| Marschke, RF | 1 |
| Laurie, JA | 1 |
| Glimelius, B | 1 |
| Vaughn, CB | 1 |
| Chapman, J | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Enochs, K | 1 |
| Groshko, G | 1 |
| Rocchio, R | 1 |
| Redmond, C | 1 |
| Caplan, R | 1 |
| Jones, J | 1 |
| Lerner, H | 1 |
| Panettiere, FJ | 1 |
| Goodman, PJ | 1 |
| Costanzi, JJ | 1 |
| McCracken, JD | 1 |
| Brownlee, RW | 1 |
| Laufman, L | 1 |
| Stephens, RL | 1 |
| Bonnet, J | 1 |
| Rubin, J | 2 |
| Hahn, RG | 1 |
| Case, LD | 1 |
| Jackson, DV | 2 |
| Cooper, MR | 2 |
| Zekan, P | 1 |
| Cruz, J | 1 |
| Sertoli, MR | 1 |
| Guarneri, D | 1 |
| Rubagotti, A | 1 |
| Porcile, G | 1 |
| Nobile, MT | 1 |
| Rosso, R | 1 |
| Craig, JB | 1 |
| Richards, FR | 1 |
| Neilan, BA | 1 |
| Caruso, U | 1 |
| Elli, M | 1 |
| Cravotto, E | 1 |
| Tisone, G | 1 |
| Lombardo, PA | 1 |
| Silvaroli, M | 1 |
| Ficorella, C | 1 |
| Cortesi, E | 1 |
| Casciani, CU | 1 |
| Adson, MA | 1 |
| Ilstrup, DM | 1 |
| Platinskiĭ, LV | 1 |
| Sokolova, VD | 1 |
| Ozhiganov, EL | 1 |
| Rominger, CJ | 1 |
| Gelber, RD | 2 |
| Conner, N | 1 |
| Zorzitto, ML | 1 |
| Myers, R | 1 |
| Bazos, MJ | 1 |
| Shepherd, FA | 1 |
| Evans, WK | 1 |
| Danjoux, CE | 1 |
| Catton, GE | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
15 reviews available for semustine and Rectal Neoplasms
| Article | Year |
|---|---|
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1995 |
[Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 1994 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
[The current status of postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colect | 1997 |
[Radiotherapy and chemotherapy in the treatment of cancer of the rectum].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Contro | 2000 |
Chemotherapy of colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Drug Administration Sche | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Accomplishments in surgical adjuvant therapy for large bowel cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug T | 1992 |
[Adjuvant radiotherapy in rectum carcinoma].
Topics: Combined Modality Therapy; Humans; Postoperative Care; Preoperative Care; Radiotherapy Dosage; Radio | 1992 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
[Chemotherapy of cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms | 1985 |
Methyl-CCNU inclinical cancer therapy.
Topics: Animals; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous | 1974 |
49 trials available for semustine and Rectal Neoplasms
| Article | Year |
|---|---|
Chemotherapy after palliative resection of colorectal cancer. Yorkshire Gastrointestinal Tumour Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1984 |
Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; | 1984 |
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Adjuvant therapy for colo-rectal cancer.
Topics: Adjuvants, Immunologic; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality | 1983 |
Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Clinical Trials as Topic; | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
Methyl-CCNU and ftorafur in treatment of rectosigmoidal tumors and ftorafur capsules in treatment of colorectal tumors.
Topics: Capsules; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Huma | 1981 |
Adjuvant chemotherapy of colorectal carcinoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neo | 1982 |
Combination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previously treated with 5-fluorouracil (5-Fu).
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; | 1983 |
A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Piperazines; Razoxane; Rectal Neo | 1981 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Fluor | 1994 |
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Therapy, Combination | 1994 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
[Initial experiences with a nation-wide Austrian study of adjuvant chemo- and immunotherapy of colorectal cancer following radical surgery].
Topics: Antineoplastic Agents; Austria; Colectomy; Colonic Neoplasms; Drug Therapy, Combination; Fluorouraci | 1979 |
Gastrointestinal cancer--colon (surgery-radiotherapy). The role of radiation therapy in the management of rectosigmoid cancer.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Neoplasm Me | 1977 |
Randomized trial of melphalan plus 5-fluorouracil (5-FU) versus methyl-CCNU plus 5-FU in patients with advanced colorectal cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Ther | 1978 |
Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neopl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; D | 1979 |
Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum: a prospective randomized study.
Topics: Adenocarcinoma; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1979 |
Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275).
Topics: Aldehydes; Colonic Neoplasms; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Etoposide; | 1979 |
Chemotherapy of large intestinal carcinoma. Current results and future prospects.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms | 1975 |
Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
Topics: Arylsulfatases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1977 |
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; F | 1992 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
NCI advocates use of adjuvant therapy for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Nat | 1991 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1988 |
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine | 1988 |
A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1987 |
Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1986 |
Adjuvant immunochemotherapy in colorectal cancer Dukes C.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fema | 1987 |
Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16).
Topics: Abscess; Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1985 |
Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality Therapy; Fem | 1985 |
39 other studies available for semustine and Rectal Neoplasms
| Article | Year |
|---|---|
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
Adjuvant therapy for carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; L | 1984 |
[A clinical study (phase II) of a combination of 5-fluorouracil, vincristine and methyl CCNU in patients with advanced carcinoma of the large intestine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; | 1983 |
Metastatic colorectal cancer. Combination chemotherapy in patients previously treated with 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middl | 1980 |
Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; F | 1982 |
Colorectal cancer. Chemotherapy.
Topics: Adjuvants, Pharmaceutic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; | 1982 |
Colorectal cancer. Prospects in management.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Colonic Neoplasms; Fluorouracil; Humans; Postoperat | 1982 |
Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nitrosourea Compou | 1982 |
Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1981 |
Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
Response of metastatic cloacogenic carcinoma to treatment with semustine.
Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu | 1981 |
[Current aspects of precautional therapy of colorectal neoplasms].
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Postoper | 1980 |
Comparison of two combination chemotherapy regimens in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[Adjuvant therapy after curative resection of rectal carcinoma].
Topics: Chemotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Humans; Radiotherapy, Adjuvant; Rectal | 1995 |
Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Colonic Neoplasms; Digestive System; Drug Evaluation; Drug | 1979 |
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1979 |
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Colonic Neoplasms; Drug Administration Schedule; Dr | 1979 |
Combination chemotherapy of colorectal cancer with 5-fluorouracil, methyl-1,3-cis(2-chloroethyl)-1-nitrosourea, and vincristine.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluoro | 1979 |
Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1977 |
Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Nitrosourea Comp | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combin | 1978 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combina | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1992 |
[Adjuvant treatment of resected colon cancers using a 5-fluorouracil-levamisole combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1991 |
Clinical trials referral resource. Adjuvant therapy for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1991 |
Combined-modality therapy for rectal carcinoma--the time has come.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1991 |
Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Male; Middle Aged | 1990 |
Adjuvant therapy for rectal cancer: is 5-FU effective without MeCCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Rectal Neoplasms; Semustine | 1989 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
Treatment of advanced colorectal carcinoma with actinomycin D, vincristine, methyl-CCNU, and methotrexate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dactinomycin; Female; | 1987 |
Management of cancer in the elderly. Implications of the aging process.
Topics: Aged; Aging; Colonic Neoplasms; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acu | 1985 |
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced | 1985 |
Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1986 |
Adjuvant therapy in rectal cancer: a protocol proposal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Inf | 1985 |